QCG
EWTX icon

Quadrant Capital Group’s Edgewise Therapeutics EWTX Stock Holding History

Quadrant Capital Group’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$189 Buy
+6
New +$173 ﹤0.01% 2671
2023
Q3 		– Sell
-41
Closed -$318 – 2711
2023
Q2 		$318 Buy
+41
New +$346 ﹤0.01% 2623
2022
Q4 		– Sell
-110
Closed -$1K – 2769
2022
Q3 		$1K Buy
+110
New +$1.11K ﹤0.01% 2505

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Quadrant Capital Group's EWTX Position: Q1 2026 in Review

Quadrant Capital Group opened a new position in Edgewise Therapeutics (EWTX) in Q1 2026: 6 shares worth $189. The stake represents ﹤0.01% of the portfolio and ranks #2671 among its holdings. This is a return to the name: Quadrant Capital Group previously reported a position in EWTX as recently as Q2 2023.

Quadrant Capital Group first reported a position in EWTX in Q3 2022 and has held it in 3 quarters since. The position peaked at $1K in Q3 2022. 214 funds tracked by Wall St. Rank hold EWTX as of Q1 2026.

  • Quadrant Capital Group held 6 shares of Edgewise Therapeutics worth $189 as of Q1 2026.
  • Edgewise Therapeutics was a new Quadrant Capital Group position in Q1 2026.
  • Edgewise Therapeutics made up ﹤0.01% of Quadrant Capital Group's portfolio in Q1 2026, its #2671 holding.
  • Quadrant Capital Group first reported a position in Edgewise Therapeutics in Q3 2022 and has held it in 3 quarters since.
  • Quadrant Capital Group's Edgewise Therapeutics position peaked at $1K in Q3 2022.
  • 214 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q1 2026.

Based on Quadrant Capital Group's 13F filing for Q1 2026, filed 11 May 2026.